title: The effect of folic acid on porphyrin synthesis in tumors and normal skin of mice treated with 5-aminolevulinic acid or methyl 5-aminolevulinate.
abstract: 5-Aminolevulinic acid (ALA) or its derivative methyl 5-aminolevulinate (MAL) combined with folic acid was applied in nude mice bearing human colon adenocarcinoma. The aim of the study is to see whether folic acid may increase biosynthesis of porphyrins in tumor tissue after systemic or topical administration of ALA or MAL. The production of porphyrins was determined by spectrofluorometric measurements with an optical fibre probe. It was found that the porphyrin production after i.p injection of 200 mg kg(-1) ALA or MAL was significantly increased by i.p injection of 100 mg kg(-1) folic acid. However, in the case of topically applied 20% ALA, folic acid had no effect. In the case of topically applied 20% MAL, folic acid (i.p or topically applied) reduced the porphyrin synthesis. This might be used for the protection of normal skin against photosensitization. The effects of folic acid were similar in tumors and normal skin. Two mechanisms may explain the results: enhancement of the efficiency of the rate-limiting enzyme porphobilinogen deaminase by folic acid or interference of folic acid with the transport of ALA and MAL to and into the cells synthesizing porphyrins in the tissues. The present data seem to favour the latter mechanism. Folic acid may have a role as an adjuvant in photodynamic therapy with systemically administered ALA and its derivatives.
authors.affiliation: Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway. ma.li-wei@labmed.uio.no
authors.forename: LiWei
authors.initials: L
authors.lastname: Ma
authors.forename: Arnfinn E
authors.initials: AE
authors.lastname: Steindal
authors.forename: Asta
authors.initials: A
authors.lastname: Juzeniene
authors.forename: Vladimir
authors.initials: V
authors.lastname: Iani
authors.forename: Johan
authors.initials: J
authors.lastname: Moan
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000622:Aminolevulinic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000737:chemistry; D000818:Animals; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010778:Photochemotherapy / Q000379:methods; D011166:Porphyrins / Q000096:biosynthesis* / Q000737:chemistry; D012680:Sensitivity and Specificity; D012867:Skin / Q000187:drug effects* / Q000378:metabolism; D013050:Spectrometry, Fluorescence; D013997:Time Factors; D014183:Transplantation, Heterologous; D023041:Xenograft Model Antitumor Assays
chemical_list: D011166:Porphyrins; C475457:methyl 5-aminolevulinate; D000622:Aminolevulinic Acid; D005492:Folic Acid